Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Scientists create sheets of protein-gold arrays

In groundbreaking research, scientists have demonstrated the ability to strategically attach gold nanoparticles -- particles on the order of billionths of a meter -- to proteins so as to form sheets of protein-gold arrays.

28 Jun 2007

Adenovirus used to destroy cancer cells

With nearly $1 million in government funding, University of Rochester scientists are testing a new innovation in biotherapy by altering a common childhood respiratory virus, the adenovirus, to destroy cancer cells.

23 Jun 2007

Nanoparticle delivery system delivers cancer-suppressing gene in M. D. Anderson trial

A cancer-suppressing gene has been successfully delivered into the tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle in a phase I clinical trial at The University of Texas M. D. Anderson Cancer Center.

18 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

South Africa starts major HIV/AIDS vaccine trial

The launch of the first large-scale study to evaluate a candidate HIV vaccine on the African continent was announced today by study collaborators in the United States and South Africa. The trial will involve up to 3,000 participants at five sites throughout South Africa and is expected to continue for four years.

11 Feb 2007

Promising chemo, therapeutic viruses, cutting-edge surgery debut at M. D. Anderson Cancer Center

Brain tumor specialists at The University of Texas M. D. Anderson Cancer Center are poised on the brink of a new era.

10 May 2006

An engineered virus that tracks down and compels cancer cells to eat themselves

An engineered virus tracks down and infects the most common and deadly form of brain cancer and then kills tumor cells by forcing them to devour themselves, researchers at The University of Texas M. D. Anderson Cancer Center report.

3 May 2006

Weill Cornell experts publish review of genetic medicine

In an article published in the April issue of Nature Reviews Genetics, two experts at the Weill Medical College of Cornell University sum up the achievements, challenges and promise of a burgeoning field: genetic medicine.

3 Apr 2006

Virus could mean obesity is contagious

According to researchers in the U.S., a virus may be why some people are obese.

30 Jan 2006

Bird flu jab for chickens could halt spread of the virus

U.S. researchers say they have produced a vaccine in less than a month which completely protects chickens from the deadly H5N1 virus.

29 Jan 2006

Drug partners in fight against AIDS say measles shot could be the answer!

Major drug company GlaxoSmithKline is hoping to develop an experimental AIDS vaccine by "piggy-backing" on a shot against measles.

29 Nov 2005

GRK5's role in restenosis

Researchers at Jefferson Medical College have begun to clarify the role of a protein - and potential drug target - in the process by which arteries re-clog after treatment.

28 Nov 2005

Gene therapy potential of the protein vasostatin for treatment of pancreatic cancer

A gene responsible for the production of a protein called vasostatin may prove a promising new way of treating pancreatic cancer, suggests research published ahead of print in Gut.

15 Nov 2005

University of Alberta researchers pioneer gene therapy to restore alveoli and lung capillaries in damaged rat lungs

The good news is that medical advances in perinatal care have allowed us to save many more premature babies. The bad news is they're often at risk of developing bronchopulmonary dysplasia--a chronic lung disease caused by having to place the tiny infants on ventilators and oxygen-rich therapy for acute respiratory failure.

13 Nov 2005

Experimental HIV vaccine progresses in trials

A novel vaccine targeted to multiple HIV subtypes found worldwide has moved into the second phase of clinical testing, the National Institute of Allergy and Infectious Diseases (NIAID) announced today.

11 Oct 2005

Compounds secreted by frog skin are potent blockers of HIV infection

The findings could lead to topical treatments for preventing HIV transmission, and they reinforce the value of preserving the Earth's biodiversity.

3 Oct 2005

Possible therapy that could control blood pressure

A newly developed virus that introduces a blood pressure-lowering gene into cells and enables that gene to maintain blood pressure at healthy levels for four months promises to take gene therapy for the disorder a step closer to reality, said researchers at Baylor College of Medicine in a report released online in the Proceedings of the National Academy of Sciences.

27 Sep 2005

Fever might be a useful weapon in the fight against cancer

A therapeutic approach for battling cancer that is based on infection with a specially designed virus similar to the one that causes the common cold has shown promise in clinical trials. Now, new research suggests that fever might be a useful weapon in the fight as well.

18 Jul 2005

Partnership to develop an AIDS vaccine using a promising new technology

GlaxoSmithKline Biologicals (GSK Biologicals) and the International AIDS Vaccine Initiative (IAVI) today announced a public-private partnership to develop an AIDS vaccine using a promising new technology.

21 Jun 2005

Introgen wins European patent decision on p53 gene therapeutic

Introgen Therapeutics has announced that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office (EPO) in which all claims directed to therapeutic applications of the p53 gene, the active component of Introgen's Advexin molecular therapy, were finally revoked by the EPO's Technical Board of Appeals.

3 Jun 2005